Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis: Results from a randomised, double-blind, placebo-controlled, phase 3 trial in Japan (the TAKT study)
Annals of Rheumatic Diseases Mar 10, 2018
Nakaoka Y, et al. - Herein, the effectiveness and safety of the interleukin-6 receptor antibody tocilizumab were assessed in subjects with Takayasu arteritis (TAK). Although the primary endpoint ie, time to relapse of TAK was not met, findings suggested favour for tocilizumab over placebo for time to relapse of TAK without new safety concerns.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
